Robert Dewitt, MD
Internal Medicine · Alvin, TXNPI 1972589737
Payments from drug & device makers
Across 376 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Johnson & Johnson$807
- Novo Nordisk$802
- GSK$590
- Pfizer$398
- Boehringer Ingelheim$395
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,19599%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 52 | $1,523 |
| Johnson & Johnson | 18 | $807 |
| Novo Nordisk | 39 | $802 |
| GSK | 38 | $590 |
| Pfizer | 16 | $398 |
| Boehringer Ingelheim | 19 | $395 |
| AbbVie(2 entities) | 23 | $374 |
| Lilly USA, LLC | 16 | $350 |
| Astellas Pharma US Inc | 17 | $327 |
| Harmony Biosciences LLC | 8 | $283 |
| Novartis | 20 | $270 |
| Amgen | 18 | $262 |
| Bayer | 10 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $204 |
| Philips North America LLC | 11 | $195 |
| Exact Sciences | 11 | $175 |
| Merck | 11 | $163 |
| Pulmonx Corporation | 1 | $147 |
| Eisai Inc. | 4 | $69 |
| Boston Scientific | 2 | $56 |
| Corcept Therapeutics | 2 | $48 |
| Mylan Specialty L.p. | 2 | $46 |
| Viatris Specialty LLC | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| Dexcom, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $32 |
| Sunovion Pharmaceuticals Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Nevro Corp. | 1 | $28 |
| Medtronic | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| Abbott | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$473
- FARXIGA$347
- TRELEGY ELLIPTA$263
- CHARTIS CATHETER$147
- ZEPHYR DELIVERY CATHETER$147
- ZEPHYR ENDOBRONCHIAL VALVE$147
- PULMONX CHARTIS TABLET CONSOLE$147
- Ozempic$122
- ZEPBOUND$122
- PREVNAR 20$121
- BREZTRI$104
How this compares
$8,256 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 134 | $157,568 |
| EliquisApixaban | 144 | $138,066 |
| MounjaroTirzepatide | 49 | $65,374 |
| XareltoRivaroxaban | 65 | $58,724 |
| JardianceEmpagliflozin | 63 | $57,786 |
| FarxigaDapagliflozin Propanediol | 65 | $55,568 |
| MyrbetriqMirabegron | 45 | $36,691 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $35,432 |
| TrulicityDulaglutide | 17 | $28,780 |
| RybelsusSemaglutide | 16 | $27,681 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $27,240 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $23,410 |
| JanuviaSitagliptin Phosphate | 14 | $21,120 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $20,095 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $19,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $802 | $185,249150 claims |
| PfizerEliquis, Premarin | $398 | $145,663163 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,523 | $115,365167 claims |
| Lilly USA, LLCMounjaro, Trulicity | $350 | $94,15466 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $395 | $77,50491 claims |
| Johnson & JohnsonXarelto | $807 | $58,72465 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $590 | $53,44278 claims |
| MerckJanuvia, Janumet | $163 | $39,24729 claims |
| Astellas Pharma US IncMyrbetriq | $327 | $36,69145 claims |
| NovartisEntresto | $270 | $13,14220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Alvin
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.